CLINICAL TRIALS PROFILE FOR SKLICE
✉ Email this page to a colleague
All Clinical Trials for SKLICE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03257943 ↗ | A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5% | Completed | Taro Pharmaceuticals USA | Phase 1 | 2017-03-20 | A Multi-Center, Double-Blind, Randomized, Placebo controlled, Parallel-group study, comparing Ivermectin Lotion, 0.5% |
| NCT03301649 ↗ | Clinical Endpoint Study of Ivermectin 0.5% Lotion | Completed | Teva Pharmaceuticals USA | Phase 3 | 2017-10-07 | This clinical study is designed to evaluate the clinical (therapeutic) effect of a generic ivermectin lotion 0.5% (Actavis Laboratories UT, Inc.) relative to that of the Food and Drug Administration (FDA) Reference Listed Drug (RLD) SKLICE® (ivermectin) lotion, 0.5% (Arbor Pharmaceuticals, LLC) in participants with active head lice infestation. Additionally, both the test and reference (that is; the RLD) treatments were tested for superiority to a placebo. |
| NCT03301649 ↗ | Clinical Endpoint Study of Ivermectin 0.5% Lotion | Completed | Actavis Inc. | Phase 3 | 2017-10-07 | This clinical study is designed to evaluate the clinical (therapeutic) effect of a generic ivermectin lotion 0.5% (Actavis Laboratories UT, Inc.) relative to that of the Food and Drug Administration (FDA) Reference Listed Drug (RLD) SKLICE® (ivermectin) lotion, 0.5% (Arbor Pharmaceuticals, LLC) in participants with active head lice infestation. Additionally, both the test and reference (that is; the RLD) treatments were tested for superiority to a placebo. |
| NCT03337490 ↗ | A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice | Completed | bioRASI, LLC | Phase 3 | 2017-10-02 | This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study. |
| NCT03337490 ↗ | A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice | Completed | Mayne Pharma International Pty Ltd | Phase 3 | 2017-10-02 | This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study. |
| NCT04374279 ↗ | Trial to Promote Recovery From COVID-19 With Endocrine Therapy | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | 2021-04-01 | Patients with COVID-19 requiring inpatient hospitalization will be randomized to treatment with standard of care or standard of care + bicalutamide. This will be a randomized, open-label study to determine if bicalutamide improves the rate of clinical improvement in patients with COVID-19. |
| NCT05318469 ↗ | Ivermectin and Pembrolizumab for the Treatment of Metastatic Triple Negative Breast Cancer | Not yet recruiting | National Cancer Institute (NCI) | Phase 2 | 2022-06-10 | This phase II trial studies the side effects and best dose of ivermectin in combination with pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivermectin may help block the formation of growths that may become cancer. Giving ivermectin with pembrolizumab may increase the effect of pembrolizumab in shrinking tumors in patients with triple negative breast cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SKLICE
Condition Name
Clinical Trial Locations for SKLICE
Trials by Country
Clinical Trial Progress for SKLICE
Clinical Trial Phase
Clinical Trial Sponsors for SKLICE
Sponsor Name
